How to Choose the Right Route of Estrogen Therapy
Estrogen therapy is the cornerstone of menopausal hormone therapy for women, yet the route by which estrogen is delivered, whether by oral tablet, transdermal patch, gel, cream, or vaginal ovule, is still confusing. There are so many choices!
At The Pharmacy Lab, patient education is central to supporting informed decisions about hormone therapy. The following overview summarizes the clinical evidence behind each route of estrogen delivery and outlines how a compounding pharmacy such as The Pharmacy Lab supports individualized care.
Why Route of Administration Matters
Whether it is taken by mouth, applied on your skin, or inserted vaginally, the chosen route determines how estrogen is absorbed, distributed, metabolized, and cleared from the body. This distinction extends well beyond convenience, influencing both therapeutic outcomes and risk profile.
Oral Estrogen
Oral estradiol remains among the most widely prescribed forms of estrogen therapy and has evidence for improving hot flashes, night sweats, mood disturbances, brain fog, vaginal dryness, painful sex, among other symptoms related to low estrogen.
However, oral estrogens are metabolized by the liver, which converts the active Estradiol to a weaker version of Estrogen called Estrone. This processing by the liver not only means a larger amount needs to be taken but orally administered may be associated with a higher risk of venous blood clots, stroke and deep vein thrombosis compared with transdermal estrogen.
The absolute risk remains low for a healthy woman in her 40s or 50s, but rises with age, obesity, smoking, immobility, thrombophilia, prior VTE, cancer and higher estrogen doses. Risk is generally greatest during the first one to two years.
Transdermal Estrogen
Systemic estradiol patches and gels are absorbed through the skin and into the bloodstream, avoiding the initial processing by the liver that occurs with oral estrogen. As a result, transdermal estradiol has less effect on blood-clotting proteins, triglycerides and inflammatory markers. Research suggests it may carry a lower risk of blood clots, gallbladder disease and possibly stroke than oral estrogen.
Both oral and transdermal estrogen effectively treat hot flashes and help prevent bone loss. For people with certain risk factors, including obesity, migraines, elevated triglycerides or an increased risk of blood clots, transdermal estradiol may be preferred. However, anyone with a history of blood clots or a known clotting disorder requires an individualized medical assessment because transdermal estrogen does not eliminate all the risks associated with systemic menopausal hormone therapy.
Vaginal Estrogen
For patients whose main concerns are vaginal dryness, burning, irritation, painful sex, urinary urgency or recurrent urinary tract infections, low-dose vaginal estradiol delivers estrogen directly to the affected tissues.
Available as creams, tablets, and inserts it helps restore vaginal moisture, thickness and elasticity, supports the tissues surrounding the bladder and urethra, and may reduce recurrent urinary tract infections. These symptoms, collectively known as genitourinary syndrome of menopause, often worsen over time without treatment and commonly return when treatment is stopped.
Vaginal estrogens can also be safely and commonly used alongside systemic estrogen (your oral or transdermal estrogen) when vaginal or urinary symptoms are not fully relieved by systemic therapy alone. Because systemic absorption is very low, low-dose vaginal estradiol has not been associated with an increased risk of blood clots and typically does not require additional progestogen for endometrial protection. Patients with a history of estrogen-sensitive cancer should discuss treatment with their healthcare team.
Compounded and Alternative Delivery Options
At The Pharmacy Lab, we compound individualized estrogen formulations for patients whose needs are not fully met by commercially available products or who have difficulty finding the right dose or dosage form.
Options may include Bi-Est, a systemic transdermal cream containing estradiol and estriol, or vaginal estriol cream for genitourinary symptoms of menopause.
Estriol is a naturally occurring bioidentical estrogen that is less potent than estradiol and shows greater relative activity at estrogen receptor beta than estrogen receptor alpha in laboratory studies. However, this has not been proven to provide a lower risk of breast cancer, endometrial cancer or blood clots.
Compounded therapy is not inherently safer than commercial hormone therapy, but it can provide greater dosing flexibility when standard products are unsuitable. These formulations require a prescription and should be selected with a qualified healthcare provider. Patients with a uterus using systemic Bi-Est also require appropriate endometrial protection.
Clinical Considerations
There is no single form of estrogen that is right for everyone. The best option depends on your symptoms, health history, personal risk factors and preferences. How estrogen is delivered can be just as important as the dose itself, which is why treatment should always be individualized. If you are considering menopausal hormone therapy or have not found the right option, a Hormone Specialist Pharmacist at The Pharmacy Lab can help you understand the available formulations and work with your healthcare provider to find an approach that balances effective symptom relief with safety.
References
American College of Obstetricians and Gynecologists. (2013). Postmenopausal Estrogen Therapy Route of administration and risk of venous thromboembolism https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/04/postmenopa usal-estrogen-therapy-route-of-administration-and-risk-of-venous-thromboembolism
Valdes A, Patel P, Bajaj T. Estrogen Therapy. [Updated 2025 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541051/
Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, Montori VM, Faubion SS, Murad MH. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015 Nov;100(11):4012-20. doi: 10.1210/jc.2015-2237. PMID: 26544651.
